Review



boc 1  (Valiant Co Ltd)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Valiant Co Ltd boc 1
    Boc 1, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/0215279905/N-T-BOC-Met-Leu-Phe/10__1074_slash_jbc__m117__800391-211-0-4
    Average 90 stars, based on 5 article reviews
    boc 1 - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Activity Assay:

    Article Title: Formyl Peptide Receptors and Annexin A1: Complementary Mechanisms to Infliximab in Murine Experimental Colitis and Crohn’s Disease
    Article Snippet: and non-treated DSS mice received vehicle (sterile saline 0.9% + DMSO 0.5%) intraperitoneally (i.p.) on days 0–9. .. DSS-treated groups received i.p. IFX (1 mg/kg; Remicade ® Janssen-Cilag, Buenos Aires, Argentina) on day 1 and/or FPR antagonist Boc-2 (10 μg/kg; N-t-BOC-MET-LEU-PHE, MP Biomedicals, Irvine, CA, USA) on days 0–9. .. Body weight, diarrhea, and rectal bleeding were scored daily to provide the Disease Activity Index (DAI).

    Article Title: The resolution of acute inflammation induced by cyclic AMP is dependent on annexin A1
    Article Snippet: also used AntiAnxA1 (#713400) from Invitrogen (Carlsbad, CA, USA). .. BOC-1 (N-t-Boc-Met-Leu-Phe) was from MP Biomedicals (California, USA). .. Polyclonal anti-Ser27-AnxA1 antibody was generated as previously desc

    Article Title: Proresolving Actions of Synthetic and Natural Protease Inhibitors Are Mediated by Annexin A1.
    Article Snippet: and LPS (from Escherichia coli serotype O:111:B4) were from Sigma-Aldrich. .. BOC-1 (N-t-Boc-Met-leu-Phe) was from MP Biomedicals (Santa Ana, CA). .. ZVAD-fmk was from Tocris (Ellisville, MO).

    Article Title: Inflammation and Cancer: Role of Annexin A1 and FPR2/ALX in Proliferation and Metastasis in Human Laryngeal Squamous Cell Carcinoma
    Article Snippet: hours later, after the cells had already adhered, they were incubated in serum-free medium to synchronize the cell cycle. .. After an additional 24 hours, the medium was replaced with complete growth medium containing the following: (a) 1 µM of ANXA1 2–26 peptide (Ac-AMVSEFLKQAWFIENEEQEYVQTVK) (Invitrogen); (b) 1 µM of ANXA1 2–26 peptide and 10 µM Boc2, a nonselective FPR antagonist (N-t-BOC-MET-LEU-PHE) (MP Biomedicals, Aurora, OH); (c) 0.01 µM dexamethasone (a glucocorticoid; Sigma-Aldrich, St. Louis, MO, USA); (d) 0.01 µM dexamethasone and 10 µM Boc2; or (e) 10 µM Boc2 alone. .. The drugs were first dissolved in small amounts of dimethyl sulfoxide (DMSO) and then diluted in medium (the final concentration of D

    Histopathology:

    Article Title: Formyl Peptide Receptors and Annexin A1: Complementary Mechanisms to Infliximab in Murine Experimental Colitis and Crohn’s Disease
    Article Snippet: and non-treated DSS mice received vehicle (sterile saline 0.9% + DMSO 0.5%) intraperitoneally (i.p.) on days 0–9. .. DSS-treated groups received i.p. IFX (1 mg/kg; Remicade ® Janssen-Cilag, Buenos Aires, Argentina) on day 1 and/or FPR antagonist Boc-2 (10 μg/kg; N-t-BOC-MET-LEU-PHE, MP Biomedicals, Irvine, CA, USA) on days 0–9. .. Body weight, diarrhea, and rectal bleeding were scored daily to provide the Disease Activity Index (DAI).

    Article Title: The resolution of acute inflammation induced by cyclic AMP is dependent on annexin A1
    Article Snippet: also used AntiAnxA1 (#713400) from Invitrogen (Carlsbad, CA, USA). .. BOC-1 (N-t-Boc-Met-Leu-Phe) was from MP Biomedicals (California, USA). .. Polyclonal anti-Ser27-AnxA1 antibody was generated as previously desc

    Article Title: Proresolving Actions of Synthetic and Natural Protease Inhibitors Are Mediated by Annexin A1.
    Article Snippet: and LPS (from Escherichia coli serotype O:111:B4) were from Sigma-Aldrich. .. BOC-1 (N-t-Boc-Met-leu-Phe) was from MP Biomedicals (Santa Ana, CA). .. ZVAD-fmk was from Tocris (Ellisville, MO).

    Article Title: Inflammation and Cancer: Role of Annexin A1 and FPR2/ALX in Proliferation and Metastasis in Human Laryngeal Squamous Cell Carcinoma
    Article Snippet: hours later, after the cells had already adhered, they were incubated in serum-free medium to synchronize the cell cycle. .. After an additional 24 hours, the medium was replaced with complete growth medium containing the following: (a) 1 µM of ANXA1 2–26 peptide (Ac-AMVSEFLKQAWFIENEEQEYVQTVK) (Invitrogen); (b) 1 µM of ANXA1 2–26 peptide and 10 µM Boc2, a nonselective FPR antagonist (N-t-BOC-MET-LEU-PHE) (MP Biomedicals, Aurora, OH); (c) 0.01 µM dexamethasone (a glucocorticoid; Sigma-Aldrich, St. Louis, MO, USA); (d) 0.01 µM dexamethasone and 10 µM Boc2; or (e) 10 µM Boc2 alone. .. The drugs were first dissolved in small amounts of dimethyl sulfoxide (DMSO) and then diluted in medium (the final concentration of D

    Staining:

    Article Title: Formyl Peptide Receptors and Annexin A1: Complementary Mechanisms to Infliximab in Murine Experimental Colitis and Crohn’s Disease
    Article Snippet: and non-treated DSS mice received vehicle (sterile saline 0.9% + DMSO 0.5%) intraperitoneally (i.p.) on days 0–9. .. DSS-treated groups received i.p. IFX (1 mg/kg; Remicade ® Janssen-Cilag, Buenos Aires, Argentina) on day 1 and/or FPR antagonist Boc-2 (10 μg/kg; N-t-BOC-MET-LEU-PHE, MP Biomedicals, Irvine, CA, USA) on days 0–9. .. Body weight, diarrhea, and rectal bleeding were scored daily to provide the Disease Activity Index (DAI).

    Article Title: The resolution of acute inflammation induced by cyclic AMP is dependent on annexin A1
    Article Snippet: also used AntiAnxA1 (#713400) from Invitrogen (Carlsbad, CA, USA). .. BOC-1 (N-t-Boc-Met-Leu-Phe) was from MP Biomedicals (California, USA). .. Polyclonal anti-Ser27-AnxA1 antibody was generated as previously desc

    Article Title: Proresolving Actions of Synthetic and Natural Protease Inhibitors Are Mediated by Annexin A1.
    Article Snippet: and LPS (from Escherichia coli serotype O:111:B4) were from Sigma-Aldrich. .. BOC-1 (N-t-Boc-Met-leu-Phe) was from MP Biomedicals (Santa Ana, CA). .. ZVAD-fmk was from Tocris (Ellisville, MO).

    Article Title: Inflammation and Cancer: Role of Annexin A1 and FPR2/ALX in Proliferation and Metastasis in Human Laryngeal Squamous Cell Carcinoma
    Article Snippet: hours later, after the cells had already adhered, they were incubated in serum-free medium to synchronize the cell cycle. .. After an additional 24 hours, the medium was replaced with complete growth medium containing the following: (a) 1 µM of ANXA1 2–26 peptide (Ac-AMVSEFLKQAWFIENEEQEYVQTVK) (Invitrogen); (b) 1 µM of ANXA1 2–26 peptide and 10 µM Boc2, a nonselective FPR antagonist (N-t-BOC-MET-LEU-PHE) (MP Biomedicals, Aurora, OH); (c) 0.01 µM dexamethasone (a glucocorticoid; Sigma-Aldrich, St. Louis, MO, USA); (d) 0.01 µM dexamethasone and 10 µM Boc2; or (e) 10 µM Boc2 alone. .. The drugs were first dissolved in small amounts of dimethyl sulfoxide (DMSO) and then diluted in medium (the final concentration of D



    Similar Products

    fpr antagonist boc 2  (Valiant Co Ltd)
    90
    Valiant Co Ltd fpr antagonist boc 2
    Formyl peptide receptor (FPR) blockade impairs clinical and histological improvements induced by infliximab (IFX) during colitis. (A) Loss of body weight. (B) Disease Activity Index (DAI). (C) Area under the curve from DAI, early and late phases. (D, E) Colon length and anatomic changes. (F) Colonic MMP-9 levels. Mean of all samples ( continuous lines ). Bar , 1 cm. aa p < 0.01 (DSS vs. Control); b p < 0.05 (DSS+IFX vs. DSS); c p < 0.05 <t>(DSS+Boc-2</t> vs. DSS); d p < 0.05 (DSS+IFX+Boc-2 vs. DSS); e p < 0.05, ee p < 0.01, eee p < 0.001 (DSS+IFX+Boc-2 vs. DSS+IFX). * p < 0.05, ** p < 0.01, *** p < 0.001. n = 4–6 mice/group. Results are expressed as the mean ± SEM. (G–K) Histopathology in wild-type (WT) groups. Ulcer ( black arrows ), altered crypts ( white arrows ), crypt abscesses ( white arrowheads ), edema ( Ed ), and inflammatory infiltrate ( circles ). Staining, hematoxylin–eosin; embedding, paraffin; sections, 3 μm. Bars , 20 μm.
    Fpr Antagonist Boc 2, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/0215279905/N-T-BOC-Met-Leu-Phe/pmc08484756-71-17-23
    Average 90 stars, based on 1 article reviews
    fpr antagonist boc 2 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    boc 1  (Valiant Co Ltd)
    90
    Valiant Co Ltd boc 1
    Formyl peptide receptor (FPR) blockade impairs clinical and histological improvements induced by infliximab (IFX) during colitis. (A) Loss of body weight. (B) Disease Activity Index (DAI). (C) Area under the curve from DAI, early and late phases. (D, E) Colon length and anatomic changes. (F) Colonic MMP-9 levels. Mean of all samples ( continuous lines ). Bar , 1 cm. aa p < 0.01 (DSS vs. Control); b p < 0.05 (DSS+IFX vs. DSS); c p < 0.05 <t>(DSS+Boc-2</t> vs. DSS); d p < 0.05 (DSS+IFX+Boc-2 vs. DSS); e p < 0.05, ee p < 0.01, eee p < 0.001 (DSS+IFX+Boc-2 vs. DSS+IFX). * p < 0.05, ** p < 0.01, *** p < 0.001. n = 4–6 mice/group. Results are expressed as the mean ± SEM. (G–K) Histopathology in wild-type (WT) groups. Ulcer ( black arrows ), altered crypts ( white arrows ), crypt abscesses ( white arrowheads ), edema ( Ed ), and inflammatory infiltrate ( circles ). Staining, hematoxylin–eosin; embedding, paraffin; sections, 3 μm. Bars , 20 μm.
    Boc 1, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/0215279905/N-T-BOC-Met-Leu-Phe/10__1074_slash_jbc__m117__800391-211-0-4
    Average 90 stars, based on 1 article reviews
    boc 1 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    nonselective fpr antagonist  (Valiant Co Ltd)
    90
    Valiant Co Ltd nonselective fpr antagonist
    Formyl peptide receptor (FPR) blockade impairs clinical and histological improvements induced by infliximab (IFX) during colitis. (A) Loss of body weight. (B) Disease Activity Index (DAI). (C) Area under the curve from DAI, early and late phases. (D, E) Colon length and anatomic changes. (F) Colonic MMP-9 levels. Mean of all samples ( continuous lines ). Bar , 1 cm. aa p < 0.01 (DSS vs. Control); b p < 0.05 (DSS+IFX vs. DSS); c p < 0.05 <t>(DSS+Boc-2</t> vs. DSS); d p < 0.05 (DSS+IFX+Boc-2 vs. DSS); e p < 0.05, ee p < 0.01, eee p < 0.001 (DSS+IFX+Boc-2 vs. DSS+IFX). * p < 0.05, ** p < 0.01, *** p < 0.001. n = 4–6 mice/group. Results are expressed as the mean ± SEM. (G–K) Histopathology in wild-type (WT) groups. Ulcer ( black arrows ), altered crypts ( white arrows ), crypt abscesses ( white arrowheads ), edema ( Ed ), and inflammatory infiltrate ( circles ). Staining, hematoxylin–eosin; embedding, paraffin; sections, 3 μm. Bars , 20 μm.
    Nonselective Fpr Antagonist, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/0215279905/N-T-BOC-Met-Leu-Phe/pmc04260827-59-37-41
    Average 90 stars, based on 1 article reviews
    nonselective fpr antagonist - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    fpr antagonist n tert butoxycarbonyl met leu phe boc  (Valiant Co Ltd)
    90
    Valiant Co Ltd fpr antagonist n tert butoxycarbonyl met leu phe boc
    Formyl peptide receptor (FPR) blockade impairs clinical and histological improvements induced by infliximab (IFX) during colitis. (A) Loss of body weight. (B) Disease Activity Index (DAI). (C) Area under the curve from DAI, early and late phases. (D, E) Colon length and anatomic changes. (F) Colonic MMP-9 levels. Mean of all samples ( continuous lines ). Bar , 1 cm. aa p < 0.01 (DSS vs. Control); b p < 0.05 (DSS+IFX vs. DSS); c p < 0.05 <t>(DSS+Boc-2</t> vs. DSS); d p < 0.05 (DSS+IFX+Boc-2 vs. DSS); e p < 0.05, ee p < 0.01, eee p < 0.001 (DSS+IFX+Boc-2 vs. DSS+IFX). * p < 0.05, ** p < 0.01, *** p < 0.001. n = 4–6 mice/group. Results are expressed as the mean ± SEM. (G–K) Histopathology in wild-type (WT) groups. Ulcer ( black arrows ), altered crypts ( white arrows ), crypt abscesses ( white arrowheads ), edema ( Ed ), and inflammatory infiltrate ( circles ). Staining, hematoxylin–eosin; embedding, paraffin; sections, 3 μm. Bars , 20 μm.
    Fpr Antagonist N Tert Butoxycarbonyl Met Leu Phe Boc, supplied by Valiant Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/0215279905/N-T-BOC-Met-Leu-Phe/pm18056353-63-1-8
    Average 90 stars, based on 1 article reviews
    fpr antagonist n tert butoxycarbonyl met leu phe boc - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Formyl peptide receptor (FPR) blockade impairs clinical and histological improvements induced by infliximab (IFX) during colitis. (A) Loss of body weight. (B) Disease Activity Index (DAI). (C) Area under the curve from DAI, early and late phases. (D, E) Colon length and anatomic changes. (F) Colonic MMP-9 levels. Mean of all samples ( continuous lines ). Bar , 1 cm. aa p < 0.01 (DSS vs. Control); b p < 0.05 (DSS+IFX vs. DSS); c p < 0.05 (DSS+Boc-2 vs. DSS); d p < 0.05 (DSS+IFX+Boc-2 vs. DSS); e p < 0.05, ee p < 0.01, eee p < 0.001 (DSS+IFX+Boc-2 vs. DSS+IFX). * p < 0.05, ** p < 0.01, *** p < 0.001. n = 4–6 mice/group. Results are expressed as the mean ± SEM. (G–K) Histopathology in wild-type (WT) groups. Ulcer ( black arrows ), altered crypts ( white arrows ), crypt abscesses ( white arrowheads ), edema ( Ed ), and inflammatory infiltrate ( circles ). Staining, hematoxylin–eosin; embedding, paraffin; sections, 3 μm. Bars , 20 μm.

    Journal: Frontiers in Immunology

    Article Title: Formyl Peptide Receptors and Annexin A1: Complementary Mechanisms to Infliximab in Murine Experimental Colitis and Crohn’s Disease

    doi: 10.3389/fimmu.2021.714138

    Figure Lengend Snippet: Formyl peptide receptor (FPR) blockade impairs clinical and histological improvements induced by infliximab (IFX) during colitis. (A) Loss of body weight. (B) Disease Activity Index (DAI). (C) Area under the curve from DAI, early and late phases. (D, E) Colon length and anatomic changes. (F) Colonic MMP-9 levels. Mean of all samples ( continuous lines ). Bar , 1 cm. aa p < 0.01 (DSS vs. Control); b p < 0.05 (DSS+IFX vs. DSS); c p < 0.05 (DSS+Boc-2 vs. DSS); d p < 0.05 (DSS+IFX+Boc-2 vs. DSS); e p < 0.05, ee p < 0.01, eee p < 0.001 (DSS+IFX+Boc-2 vs. DSS+IFX). * p < 0.05, ** p < 0.01, *** p < 0.001. n = 4–6 mice/group. Results are expressed as the mean ± SEM. (G–K) Histopathology in wild-type (WT) groups. Ulcer ( black arrows ), altered crypts ( white arrows ), crypt abscesses ( white arrowheads ), edema ( Ed ), and inflammatory infiltrate ( circles ). Staining, hematoxylin–eosin; embedding, paraffin; sections, 3 μm. Bars , 20 μm.

    Article Snippet: DSS-treated groups received i.p. IFX (1 mg/kg; Remicade ® Janssen-Cilag, Buenos Aires, Argentina) on day 1 and/or FPR antagonist Boc-2 (10 μg/kg; N-t-BOC-MET-LEU-PHE, MP Biomedicals, Irvine, CA, USA) on days 0–9.

    Techniques: Activity Assay, Histopathology, Staining

    Crypt regeneration mediated by infliximab (IFX) requires formyl peptide receptor (FPR) signaling. (A) Control: cylindrical-shaped cells forming a U-shaped crypt revealed by β-actin staining ( a1 , red ). Presence of villin ( a2 , green ) in the inner surface from the excretory part of the crypt lumen. Representation of a normal structure. (B) DSS+IFX: preserved crypt morphology resembling the control condition ( b1 and b2 ). (C) DSS+IFX+Boc-2: defects in crypt closure ( c1 ); presence of villin ( c2 and c3 , white arrowheads ); and DNA residue ( c2 and c3 , black arrowheads ) in the crypt lumen. n = 4–6 mice/group. Embedding, paraffin; sections, 3 μm. Bars, 20 μm.

    Journal: Frontiers in Immunology

    Article Title: Formyl Peptide Receptors and Annexin A1: Complementary Mechanisms to Infliximab in Murine Experimental Colitis and Crohn’s Disease

    doi: 10.3389/fimmu.2021.714138

    Figure Lengend Snippet: Crypt regeneration mediated by infliximab (IFX) requires formyl peptide receptor (FPR) signaling. (A) Control: cylindrical-shaped cells forming a U-shaped crypt revealed by β-actin staining ( a1 , red ). Presence of villin ( a2 , green ) in the inner surface from the excretory part of the crypt lumen. Representation of a normal structure. (B) DSS+IFX: preserved crypt morphology resembling the control condition ( b1 and b2 ). (C) DSS+IFX+Boc-2: defects in crypt closure ( c1 ); presence of villin ( c2 and c3 , white arrowheads ); and DNA residue ( c2 and c3 , black arrowheads ) in the crypt lumen. n = 4–6 mice/group. Embedding, paraffin; sections, 3 μm. Bars, 20 μm.

    Article Snippet: DSS-treated groups received i.p. IFX (1 mg/kg; Remicade ® Janssen-Cilag, Buenos Aires, Argentina) on day 1 and/or FPR antagonist Boc-2 (10 μg/kg; N-t-BOC-MET-LEU-PHE, MP Biomedicals, Irvine, CA, USA) on days 0–9.

    Techniques: Staining